EP3389656A4 - Kombinationen von opioid-rezeptorliganden und cytochrom-p450-inhibitoren - Google Patents

Kombinationen von opioid-rezeptorliganden und cytochrom-p450-inhibitoren Download PDF

Info

Publication number
EP3389656A4
EP3389656A4 EP16876711.9A EP16876711A EP3389656A4 EP 3389656 A4 EP3389656 A4 EP 3389656A4 EP 16876711 A EP16876711 A EP 16876711A EP 3389656 A4 EP3389656 A4 EP 3389656A4
Authority
EP
European Patent Office
Prior art keywords
cytochrome
inhibitors
combinations
opioid receptor
receptor ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16876711.9A
Other languages
English (en)
French (fr)
Other versions
EP3389656A1 (de
Inventor
Jonathan D. Violin
David G. SOERGEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trevena Inc
Original Assignee
Trevena Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevena Inc filed Critical Trevena Inc
Publication of EP3389656A1 publication Critical patent/EP3389656A1/de
Publication of EP3389656A4 publication Critical patent/EP3389656A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16876711.9A 2015-12-17 2016-12-15 Kombinationen von opioid-rezeptorliganden und cytochrom-p450-inhibitoren Withdrawn EP3389656A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562268874P 2015-12-17 2015-12-17
PCT/US2016/067006 WO2017106547A1 (en) 2015-12-17 2016-12-15 Combinations of opioid receptor ligands and cytochrome p450 inhibitors

Publications (2)

Publication Number Publication Date
EP3389656A1 EP3389656A1 (de) 2018-10-24
EP3389656A4 true EP3389656A4 (de) 2019-06-19

Family

ID=59057591

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16876711.9A Withdrawn EP3389656A4 (de) 2015-12-17 2016-12-15 Kombinationen von opioid-rezeptorliganden und cytochrom-p450-inhibitoren

Country Status (10)

Country Link
US (1) US20190008803A1 (de)
EP (1) EP3389656A4 (de)
JP (1) JP2019503351A (de)
KR (1) KR20180094938A (de)
CN (1) CN108601775A (de)
AU (1) AU2016370860A1 (de)
CA (1) CA3008637A1 (de)
HK (1) HK1254673A1 (de)
IL (1) IL260003A (de)
WO (1) WO2017106547A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7019035B2 (ja) * 2017-09-18 2022-02-14 上海華匯拓医薬科技有限公司 μ－オピオイド受容体アゴニスト及びその調製方法及び医療分野におけるその使用
WO2020237374A1 (en) * 2019-05-28 2020-12-03 Montreal Heart Institute Picolinic acid derivatives and use thereof for treating diseases associated with elevated cholesterol
EP4092031A4 (de) 2020-01-17 2024-02-21 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Azabicyclisches substituiertes oxaspiroderivat, verfahren zu seiner herstellung und seine medizinische verwendung
CN118221680A (zh) 2020-01-17 2024-06-21 上海海雁医药科技有限公司 光学纯的氧杂螺环取代的吡咯并吡唑衍生物、其制法与医药上的用途
CN113214264B (zh) * 2020-01-21 2022-08-09 上海海雁医药科技有限公司 二氢吡咯并五元杂芳基取代的氧杂螺环衍生物、其制法与医药上的用途
EP4089088A4 (de) * 2020-08-10 2023-09-13 Chengdu Easton Biopharmaceuticals Co., Ltd. Mor-rezeptoragonistverbindung, verfahren zu ihrer herstellung und ihre verwendung
CN112694485B (zh) * 2020-09-10 2023-04-07 四川海品信医药科技有限公司 一种阿片受体激动剂噻吩类化合物及其制备方法
US20240109895A1 (en) 2020-12-29 2024-04-04 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Oxaspiro substituted pyrrolopyrazole derivative, intermediate thereof, and preparation method therefor
CN117529481A (zh) 2021-07-13 2024-02-06 上海海雁医药科技有限公司 Mor受体激动剂的药学上可接受的盐、其多晶型物及其用途
CN116075505A (zh) * 2021-08-31 2023-05-05 天地恒一制药股份有限公司 阿片受体激动剂及其制备方法和用途
CN115819171A (zh) * 2022-07-25 2023-03-21 成都苑东生物制药股份有限公司 一种mor受体激动剂合成路线中关键中间体的手性拆分方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016090158A1 (en) * 2014-12-05 2016-06-09 Purdue Pharma L.P. 6.7-cyclicmorphinan derivatives and use thereof
WO2017105881A1 (en) * 2015-12-15 2017-06-22 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating pain
WO2017106306A1 (en) * 2015-12-14 2017-06-22 Trevena, Inc. Methods of treating hyperalgesia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
US20090028873A1 (en) * 2007-07-27 2009-01-29 Auspex Pharmaceuticals, Inc. Substituted cyclohexanols
JP5912169B2 (ja) * 2011-03-23 2016-04-27 トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． オピオイド受容体リガンド並びにそれらの使用方法及び製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016090158A1 (en) * 2014-12-05 2016-06-09 Purdue Pharma L.P. 6.7-cyclicmorphinan derivatives and use thereof
WO2017106306A1 (en) * 2015-12-14 2017-06-22 Trevena, Inc. Methods of treating hyperalgesia
WO2017105881A1 (en) * 2015-12-15 2017-06-22 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017106547A1 *

Also Published As

Publication number Publication date
JP2019503351A (ja) 2019-02-07
KR20180094938A (ko) 2018-08-24
HK1254673A1 (zh) 2019-07-26
AU2016370860A1 (en) 2018-07-12
WO2017106547A1 (en) 2017-06-22
CN108601775A (zh) 2018-09-28
IL260003A (en) 2018-07-31
CA3008637A1 (en) 2017-06-22
US20190008803A1 (en) 2019-01-10
EP3389656A1 (de) 2018-10-24

Similar Documents

Publication Publication Date Title
HK1254673A1 (zh) 阿片受體配體和細胞色素p450抑製劑
EP3213592A4 (de) Systeme und verfahren für verbesserte mobilfunkerfahrungsqualität
EP3368541A4 (de) Zusammensetzungen und verfahren zur hemmung der arginaseaktivität
EP3380101A4 (de) Eif4-a-hemmende verbindungen und verfahren im zusammenhang damit
EP3102576B8 (de) Dihydropyrrolopyridininhibitoren von ror-gamma
EP3172213A4 (de) Makrocyclische kinasehemmer und verwendungen davon
EP3110497A4 (de) Verfahren und vorrichtungen für benutzersteuerung von neurostimulation
EP3313410A4 (de) Zusammensetzungen und verfahren zur hemmung der arginaseaktivität
EP3169363A4 (de) Verfahren zur behandlung von krebs mit tigit-inhibitoren und antikrebsmitteln
EP3286164A4 (de) Selektive liganden des androgenrezeptordegraders (sard) und verfahren zur verwendung davon
EP3110820A4 (de) Tyk2-inhibitoren und verwendungen davon
EP3200787A4 (de) Inhibitoren der irak4-aktivität
EP3233846A4 (de) Inhibitoren von bromdomänen
EP3200788A4 (de) Inhibitoren der irak4-aktivität
EP3405577A4 (de) Zusammensetzungen und verfahren zur hemmung des faktors d
EP3285757A4 (de) Selektive liganden des androgenrezeptordegraders (sard) und verfahren zur verwendung davon
EP3373969A4 (de) Glycaninteragierende verbindungen und verfahren zur verwendung
EP3200802A4 (de) Zusammensetzungen und verfahren zur aufrechterhaltung der kognitiven funktion
EP3199502A4 (de) Feuerfeste konstruktion und verfahren zur verwendung davon
EP3117450A4 (de) Zusammensetzungen und verfahren für chemisch-mechanisches polieren von wolframmaterialien
EP3107902A4 (de) Verbindungen und verfahren zur hemmung von fascin
EP3213493A4 (de) Umgebungsbasierte komplexitätsverringerung zur audioverarbeitung
EP3177327A4 (de) Inhibitoren von myh7b und verwendungen davon
EP3116489A4 (de) Verfahren und zusammensetzung zur transdermalen verabreichung
EP3262157A4 (de) Umprogrammierung von vorläuferzusammensetzungen und verfahren zur verwendung dafür

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180627

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190522

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/444 20060101ALI20190516BHEP

Ipc: A61K 31/4436 20060101ALI20190516BHEP

Ipc: A61K 31/4433 20060101ALI20190516BHEP

Ipc: A61K 31/439 20060101AFI20190516BHEP

Ipc: A61P 25/04 20060101ALI20190516BHEP

Ipc: A61K 31/165 20060101ALI20190516BHEP

Ipc: A61K 45/06 20060101ALI20190516BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1254673

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191218